SCHEMBL7540134

SCHEMBL7540134

COc1ccc(S(=O)(=O)c2ccc(S(=O)(=O)c3ccccc3)c(C#N)c2)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
HTR6 P50406 1/20 0.46
ABCC9 O60706 1/20 0.45
ABCC8 Q09428 1/20 0.45
KCNJ11 Q14654 1/20 0.45
KCNJ8 Q15842 1/20 0.45
SLC22A12 Q96S37 4/20 0.42
POLB P06746 2/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
NAMPT P43490 3/20 0.42
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
SCN9A Q15858 1/20 0.41
HSD11B1 P28845 1/20 0.41
HPGD P15428 2/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7533132 0.86 LMNA (0.50) KMT2AMEN1HTR6ABCC9ABCC8
SCHEMBL7534915 0.84 KDM4E (0.52) KDM4EKMT2AMEN1HTR6ABCC9
SCHEMBL7540327 0.83 POLB (0.50) KMT2ASLC22A12POLBTSHRMAPK1
SCHEMBL8059950 0.82 MEN1 (0.40) KMT2AMEN1ABCC9ABCC8KCNJ11
SCHEMBL12504669 0.79 ACLY (0.51) KDM4EKMT2AMEN1HTR6POLB
SCHEMBL7533321 0.77 LMNA (0.60) KMT2AMEN1SLC22A12TSHRMAPK1
SCHEMBL7537146 0.75 CA12 (0.48) KMT2AMEN1HTR6ABCC9ABCC8
SCHEMBL8046997 0.74 HTR6 (0.69) KDM4EKMT2AMEN1HTR6POLB
SCHEMBL11121243 0.74 HTR6 (0.52) KDM4EHTR6ABCC9ABCC8KCNJ11
SCHEMBL10969268 0.73 POLB (0.58) KMT2AMEN1POLBTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP claimed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 KDM4E 2230/4885KMT2A 3154/4885MEN1 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.